The medical device industry: Coping with tariffs

Over the past year, the medical device industry has been forced to navigate a rapidly shifting trade environment as new and proposed tariffs reshaped the economics of manufacturing, sourcing and innovation. Although tariffs are often framed as tools to protect domestic industries, their implementation raises a host of concerns for device makers, health care providers, and ultimately patients — concerns that extend well beyond balance sheets.

Medical devices rely on highly globalized supply chains, with critical components, raw materials and subassemblies often sourced from multiple countries. Tariffs on metals, electronics and finished components increased costs at nearly every stage of production, leaving manufacturers with difficult choices: Absorb higher expenses, pass costs along to hospitals and health systems or delay investments in research and development. For an industry already operating under tight pricing pressures and regulatory constraints, even modest cost increases threatened long-term sustainability.

The uncertainty surrounding tariff policy also proved disruptive. Rapidly changing rules made it difficult for companies to plan capital investments, negotiate long-term supplier contracts or commit to expanding domestic manufacturing. Smaller and midsized device companies — often more dependent on a narrow supplier base — faced disproportionate risk, raising concerns about consolidation and reduced competition in the market.

From a clinical perspective, industry leaders warned that tariffs could slow innovation, limit product availability and exacerbate supply shortages, particularly for lower-margin but essential devices. At the same time, hospitals and physician practices worried about rising acquisition costs in an era of flat or declining reimbursement.

Taken together, these concerns underscore why tariffs became a focal point of debate within the medical device sector, highlighting the complex interplay between trade policy, health care economics and patient care. Medical Economics spoke with Casey Hite, CEO of Aeroflow Health, about the effect tariffs have had on the industry and how companies are coping.